Vanda Pharmaceuticals Inc. (VNDA) income statement
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3059% below fair value
$3.44−0.23 (-6.13%)
Close on Nov 20, 2026Market cap $208.32MP/E –Yield –
Vanda Pharmaceuticals Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 93.6%
- Operating margin
- -77.6%
- Net margin
- -119.9%
- Return on equity, FY2025
- -50.9%
Financial strength
- Current ratio
- 1.54
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 40.0%
Valuation
- P/E ratio
- –
- Price to sales
- 0.91
- Price to book
- 1.04
- Dividend yield
- –
See a number that looks wrong?